At a glance
ClinicalIndex Comparison RecordN/AActive· 3,090 enrolled / 3,090 target
Drug / intervention
Navigator-delivered Home ePROother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Implementation and Impact of Navigator-delivered ePRO Home Symptom Monitoring and Management
In Brief
A clinical study evaluating Navigator-delivered Home ePRO for Cancer. Active but no longer recruiting, targeting 3,090 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
Evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites and assess the impact of Home ePRO on clinical and utilization outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Timeline
N/AActive
202220232024202520262027
First PostedMar 2021
Enrollment StartMay 2021
Primary CompletionDec 2025
TodayJul 2026
Study CompletionFeb 2027
First PostedMar 22, 2021
Enrollment StartMay 4, 2021
Primary CompletionDec 31, 2025
Study CompletionFeb 28, 2027
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 5.3 years ago
Arms & Interventions
Patient Groupother
Patients from UAB/MCI enrolled
Other: Navigator-delivered Home ePRO
Interventions
Navigator-delivered Home ePROother
The intervention includes standard of care weekly symptom survey delivery to patients, with alerts generated for symptoms that are sent to clinic nurses to address per standard of care protocol